Evidence map›Paper›PMID 40736004›Full record

ArticleCancer immunology research2025

TIGIT Affects CAR NK-cell Effector Function in the Solid Tumor Microenvironment by Modulating Immune Synapse Strength.

Ishwar Navin, Matthew Dysthe, Prashant S Menon, Corrine Baumgartner, Tim Sauer, Navin Varadarajan, Robin Parihar

Abstract read
In one paragraph

Article in Cancer immunology research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ishwar NavinDepartment of Immunology and Microbiology, Baylor College of Medicine, Houston, Texas.ORCID 0000-0002-7397-6624
Matthew DystheDepartment of Translational Biology and Molecular Medicine, Baylor College of Medicine, Houston, Texas.ORCID 0000-0002-6559-3498
Prashant S MenonWilliam A. Brookshire Department of Chemical and Biomolecular Engineering, University of Houston, Houston, Texas.ORCID 0000-0001-6415-5202
Corrine BaumgartnerDepartment of Pediatrics, Division of Hematology-Oncology, Baylor College of Medicine, Houston, Texas.ORCID 0009-0006-6871-3770
Tim SauerDepartment of Medicine V, Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany.ORCID 0000-0001-5412-324X
Navin VaradarajanWilliam A. Brookshire Department of Chemical and Biomolecular Engineering, University of Houston, Houston, Texas.ORCID 0000-0001-7524-8228
Robin PariharDepartment of Immunology and Microbiology, Baylor College of Medicine, Houston, Texas.ORCID 0000-0002-3283-6713

Funding

MusIC: A multi-scale technology for integrating dynamic cellular function and molecular profilesR01GM143243 · NIGMS · UNIVERSITY OF HOUSTON · PI VARADARAJAN, NAVIN · 2021 to 2024
$1.8M
Alex's Lemonade Stand Foundation for Childhood Cancer (ALSF) 21-23536Cancer Prevention and Research Institute of Texas (CPRIT) RP240439Foundation for the National Institutes of Health (FNIH) R01GM143243NIGMS NIH HHS R01 GM143243
6 · The paper itself

Abstract

Therapies using NK cells that express chimeric antigen receptors (CAR-NK) have been successfully employed against hematologic malignancies. However, solid tumors resist CAR-NKs partly by enriching tumor microenvironments with ligands for NK cell inhibitory receptors. Although the NK inhibitory receptor T-cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domain (TIGIT) has been implicated in impaired antitumor activity of endogenous NK cells, the consequences of TIGIT expression on engineered CAR-NKs have not been explored. To address this gap, we compared TIGIT-expressing and TIGIT-deleted human CAR-NKs targeting the GD2 solid tumor antigen in tumor immune microenvironment co-cultures and in vivo tumor immune microenvironment xenografts designed to mimic the immunosuppressive environment of solid tumors. TIGIT-deleted GD2.CAR-NKs exhibited antitumor activity, expanded, and persisted within TIGIT ligand-enriched solid tumor environments, whereas TIGIT-expressing CAR-NKs did not. Mechanistic experiments revealed that the improved tumor control resulting from TIGIT loss on CAR-NKs was not dependent on DNAM-1 activation or enhanced cytotoxic potential but rather on downregulation of cell adhesion molecules, weakened cell avidity, and reduced synapse contact duration that, in concert, improved serial killing and allowed more efficient tumor destruction. Our study highlights a noncanonical role for TIGIT in modulating CAR-NK activity that may guide strategies to overcome inhibitory NK receptors like TIGIT and improve the efficacy of CAR-NKs against solid tumors.

Indexed as

Immunological SynapsesImmunotherapy, AdoptiveKiller Cells, NaturalNeoplasmsReceptors, Chimeric AntigenReceptors, ImmunologicTumor MicroenvironmentAnimalsCell Line, TumorHumansMiceXenograft Model Antitumor AssaysReceptors, Chimeric AntigenReceptors, ImmunologicTIGIT protein, human

Identifiers

PMID40736004
PMCPMC12453546

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.